Israeli Dr Researching New TBI Drug

Dr. Adrian Harel, is owner and president of MediCortex, operating in Israel and the US. Now in the R&D stage, the company’s goal is to bring a new multifunctional drug or innovative treatment to the market that will prevent or reduce secondary accelerated symptoms of traumatic brain injury and neurological dysfunction. Dr. Harel was educated primarily in Israel, earning advanced degrees in both Neurobiology and Business. He has worked in the field of Biotechnologies and Stem Based Therapies for over a decade. New research shows that a traumatic brain injury, even a mild one, can trigger an earlier onset of neurodegenerative disorders such as Alzheimer’s disease or Parkinson’s disease. To date, there is no drug designed specifically to treat TBI. See www.medicortex.com